Shanghai Ugene Biotechnology

Shanghai Ugene Biotechnology is a clinical-stage biopharmaceutical company dedicated to the development of innovative gene therapies for patients with severe genetic diseases. The company utilizes its proprietary U-AAV platform to optimize adeno-associated virus vectors for enhanced delivery and expression. Its lead program, UG-001, is a gene therapy targeting Leber Hereditary Optic Neuropathy (LHON) caused by the ND4 mutation and has received IND clearance from both the FDA and NMPA. Beyond ophthalmology, Ugene is expanding its pipeline to include treatments for central nervous system disorders and other rare diseases. The company is headquartered in Shanghai and maintains integrated R&D and manufacturing capabilities to support its clinical programs. Through its focus on cutting-edge viral vector technology, Ugene aims to provide transformative treatments for vision loss and neurological conditions.